For the first time, an experimental vaccine has prevented infection with the AIDS virus, a watershed event in the deadly epidemic and a surprising result. Recent failures led many scientists to think such a vaccine might never be possible.
The vaccine cut the risk of becoming infected with HIV by more than 31 percent in the world’s largest AIDS vaccine trial of more than 16,000 volunteers in Thailand, researchers announced today.
Even though the benefit is modest, “it’s the first evidence that we could have a safe and effective preventive vaccine,” said Col. Jerome Kim. He helped lead the study for the U.S. Army, which sponsored it with the National Institute of Allergy and Infectious Diseases.
The institute’s director, Dr. Anthony Fauci, warned that this is “not the end of the road,” but said he was surprised and very pleased by the outcome. “It gives me cautious optimism about the possibility of improving this result” and developing a more effective AIDS vaccine, Fauci said. “This is something that we can do.”
Even a marginally helpful vaccine could have a big impact. Every day, 7,500 people worldwide are newly infected with HIV; 2 million died of AIDS in 2007, the U.N. agency UNAIDS estimates.
“Today marks an historic milestone,” said Mitchell Warren, executive director of the AIDS Vaccine Advocacy Coalition, an international group that has worked toward developing a vaccine.
“It will take time and resources to fully analyze and understand the data, but there is little doubt that this finding will energize and redirect the AIDS vaccine field,” he said in a statement.
The Thailand Ministry of Public Health conducted the study, which used strains of HIV common in Thailand. Whether such a vaccine would work against other strains in the U.S., Africa or elsewhere in the world is unknown, scientists stressed.
The study actually tested a two-vaccine combo in a “prime-boost” approach, where the first one primes the immune system to attack HIV and the second one strengthens the response.
They are ALVAC, from Sanofi Pasteur, the vaccine division of French drugmaker Sanofi-Aventis; and AIDSVAX, originally developed by VaxGen Inc. and now held by Global Solutions for Infectious Diseases, a nonprofit founded by some former VaxGen employees.
The study tested the combo in HIV-negative Thai men and women ages 18 to 30 at average risk of becoming infected. Half received four “priming” doses of ALVAC and two “boost” doses of AIDSVAX over six months. The others received dummy shots. No one knew who got what until the study ended.
All were given condoms, counseling and treatment for any sexually transmitted infections and were tested every six months for HIV. Any who became infected were given free treatment with antiviral medicines.
Participants were followed for three years after vaccination ended.
Results: New infections occurred in 51 of the 8,197 given vaccines and in 74 of the 8,198 who received dummy shots. That worked out to a 31 percent lower risk of infection for the vaccine group.
The vaccine had no effect on levels of HIV in the blood of those who did become infected. That had been another goal of the study – seeing whether the vaccine could limit damage to the immune system and help keep infected people from developing full-blown AIDS.
Details of the $105 million study will be given at a vaccine conference in Paris in October.
GROUP TRIPS -- Hiking, paddling and birding in the Panhandle are featured in the 10th annual Summer Adventure Series of group outings led by the Idaho Conservation League. The 10 ...
High school and college football are here, so we can no longer pretend. Summer is going, going, almost gone. Yet, the weather remains nice. And the tourists are about to ...
Playing on the road in the Northwest League is never easy.
Donald Trump will hold a rally at the Xfinity Arena in Everett at 7 p.m. Tuesday, his campaign said today. The rally went up on the official campaign schedule, which ...
sponsored You’ve probably heard of co-ops: food co-ops, childcare co-ops, housing co-ops, energy co-ops.